News|Articles|July 7, 2026

First Half 2026 Recap: Gastroenterology

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

The first half of 2026 delivered meaningful progress across gastroenterology, highlighted by important regulatory milestones, encouraging late-stage clinical trial results, and continued innovation in inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and pediatric gastrointestinal care.

Related to this article

October 5th, 2026

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

October 4th, 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

October 3rd, 2026

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

October 3rd, 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

October 2nd, 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

October 2nd, 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

October 2nd, 2026

The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.

October 1st, 2026

DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.